These observations highlight the limitations of applying uniform (or “one size fits all”) NT-proBNP thresholds across populations and underscores the need for AF-specific diagnostic strategies that balance sensitivity, specificity, and healthcare resource use. This evidence concerns the gene NPPB and atrial fibrillation.